Anthony S. Gibney

IVERIC bio, Inc.Clearside Biomedical, Inc.Aura Biosciences, Inc.

Insider activity · 24 months1 buy1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 1 buy · 1 saleJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (2 ops.)

€227k

▼ Sales (2 ops.)

€6,989

Latest filing published 16 Jun 2026 for Aura Biosciences, Inc.. Read the official filing

Filing timeline

BuySale

Anthony S. Gibney

Insider track record

Disclosed buys

Disclosed sells

Signal history

Closed purchases

Market purchases

Not enough history yet: 1 closed purchase, at least 2 are needed.

Purchases by company

Aura Biosciences, Inc. 1 purchase · last 20 May 2025
Clearside Biomedical, Inc. 1 purchase · last 19 Apr 2024

Since each purchase

Aura Biosciences, Inc.
Filed 20 May 2025 · 516 days ago · €219k
+28.4%
Entry US$5.96 · Close at T+365 US$7.65

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Anthony S. Gibney: trading record in brief

Anthony S. Gibney is a declared insider at 3 companies; the most frequent names are Aura Biosciences, Inc., IVERIC bio, Inc. and Clearside Biomedical, Inc. Over a trading history stretching from 30 June 2022 to 16 June 2026, the count stands at 10 filings.

In open-market terms, that means 2 purchases worth €227k on one side and 2 sales worth €6,989 on the other. No amount is published for 1 filing, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 2 share grants and 2 option exercises. Since January 2026: no purchases and 1 sale on the market.

The latest filing, published on 16 June 2026, reports an open-market sale in Aura Biosciences, Inc. The most recent open-market purchase was published on 20 May 2025, 516 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.